Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 07:50pm CET

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
03/23 MERCK : Findings from Merck & Company in the Area of Pharmaceutical Science Repo..
03/23 MERCK : New Human Papillomavirus Findings from Merck & Company Reported (Develop..
03/23 MERCK : StayWell Earns Re-accreditation From the National Committee for Quality ..
03/22 MERCK ANIMAL HEALTH : Completes Acquisition of Vallée S.A.
03/17 MERCK : Keytruda`s head-to-head against Opdivo rockets meds to Nos. 2 and 3 in a..
03/16 MERCK & CO., INC. (NYSE : MRK) Sued By Numerous Plaintiffs Over Harm Caused By I..
03/14 MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pedia..
03/14 MERCK : Provides Update on Supplemental Biologics License Application (sBLA) for..
03/14 MERCK : Lawsuit claims Arkin misled eCam shareholders
03/13 MERCK & CO : ex-dividend day
More news
Sector news : Pharmaceuticals - NEC
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/23 Gilead Doesn't Offer A Compelling Risk/Reward
03/22 Merck loses appeal in Fosamax failure-to-warn suit; shares ease 1%
03/22 BIOLINERX : Update And Preview Of The Company's Q4 And FY 2016 Financial Results..
03/22 SNIPPET ROUNDUP : Medica And Cell Medica Are In The Money, But Endo And Valeant ..
Advertisement
Financials ($)
Sales 2017 39 720 M
EBIT 2017 13 557 M
Net income 2017 8 404 M
Debt 2017 4 038 M
Yield 2017 2,96%
P/E ratio 2017 19,73
P/E ratio 2018 16,39
EV / Sales 2017 4,49x
EV / Sales 2018 4,34x
Capitalization 174 344 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,0 $
Spread / Average Target 8,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.7.86%174 344
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
NOVARTIS AG0.47%194 072
SANOFI7.63%115 490
More Results